18 December 2017 - - Foster City, California-based global research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) executive chairman John Martin, PhD will transition from his current role of executive chairman to chairman of the board of directors, the company said.
The change will be effective on March 9, 2018.
Martin was named executive chairman on March 10, 2016, when he was succeeded as CEO by John Milligan, PhD.
He served as CEO of Gilead from 1996 to 2016, having joined the company in 1990 as the vice president of R and D.
During his time as CEO, he built the company's portfolio to 24 marketed products with annual revenues of more than USD 32bn.
Gilead Sciences discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 40 countries worldwide.